These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 15377972)

  • 21. Analytical methodology for enantiomers of salbutamol in human urine for application in doping control.
    Bergés R; Segura J; de la Torre X; Ventura R
    J Chromatogr B Biomed Sci Appl; 1999 Feb; 723(1-2):173-84. PubMed ID: 10080644
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Do inhaled beta(2)-agonists have an ergogenic potential in non-asthmatic competitive athletes?
    Kindermann W
    Sports Med; 2007; 37(2):95-102. PubMed ID: 17241101
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Determination of salbutamol enantiomers in human plasma and urine by chiral high-performance liquid chromatography.
    Boulton DW; Fawcett JP
    J Chromatogr B Biomed Appl; 1995 Oct; 672(1):103-9. PubMed ID: 8590921
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Blood and urinary concentrations of salbutamol in asthmatic subjects.
    Elers J; Pedersen L; Henninge J; Lund TK; Hemmersbach P; Dalhoff K; Backer V
    Med Sci Sports Exerc; 2010 Feb; 42(2):244-9. PubMed ID: 19927035
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-doping Policy, Therapeutic Use Exemption and Medication Use in Athletes with Asthma: A Narrative Review and Critical Appraisal of Current Regulations.
    Allen H; Backhouse SH; Hull JH; Price OJ
    Sports Med; 2019 May; 49(5):659-668. PubMed ID: 30887312
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ergogenic effects of inhaled beta2-agonists in non-asthmatic athletes.
    Wolfarth B; Wuestenfeld JC; Kindermann W
    Endocrinol Metab Clin North Am; 2010 Mar; 39(1):75-87, ix. PubMed ID: 20122451
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Asthma drugs and doping].
    Pillard F; Rolland Y; Rivière D
    Allerg Immunol (Paris); 1999 Nov; 31(9):317-9. PubMed ID: 10615514
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potential of beta2-adrenoceptor agonists as add-on therapy for multiple sclerosis: focus on salbutamol (albuterol).
    Makhlouf K; Weiner HL; Khoury SJ
    CNS Drugs; 2002; 16(1):1-8. PubMed ID: 11772115
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prescribing medications and nutritional supplements for athletes.
    Babwah T
    West Indian Med J; 2009 Sep; 58(4):352-6. PubMed ID: 20099776
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Terbutaline: level the playing field for inhaled β
    Jacobson GA; Hostrup M
    Br J Sports Med; 2017 Sep; 51(18):1323-1324. PubMed ID: 27461883
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The pharmacokinetics of levosalbutamol: what are the clinical implications?
    Boulton DW; Fawcett JP
    Clin Pharmacokinet; 2001 Jan; 40(1):23-40. PubMed ID: 11236808
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Determination of salbutamol and salbutamol glucuronide in human urine by means of liquid chromatography-tandem mass spectrometry.
    Mareck U; Guddat S; Schwenke A; Beuck S; Geyer H; Flenker U; Elers J; Backer V; Thevis M; Schänzer W
    Drug Test Anal; 2011; 3(11-12):820-7. PubMed ID: 22081503
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The use of anti-asthmatic drugs. Do they affect sports performance?
    Fitch KD
    Sports Med; 1986; 3(2):136-50. PubMed ID: 2870555
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination drug therapy for the prevention of exercise-induced bronchoconstriction in children.
    de Benedictis FM; Tuteri G; Pazzelli P; Solinas LF; Niccoli A; Parente C
    Ann Allergy Asthma Immunol; 1998 Apr; 80(4):352-6. PubMed ID: 9564987
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quantification and stability of salbutamol in human urine.
    Forsdahl G; Gmeiner G
    J Sep Sci; 2004 Jan; 27(1-2):110-4. PubMed ID: 15335066
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of exercise-induced asthma, respiratory and allergic disorders in sports and the relationship to doping: Part II of the report from the Joint Task Force of European Respiratory Society (ERS) and European Academy of Allergy and Clinical Immunology (EAACI) in cooperation with GA(2)LEN.
    Carlsen KH; Anderson SD; Bjermer L; Bonini S; Brusasco V; Canonica W; Cummiskey J; Delgado L; Del Giacco SR; Drobnic F; Haahtela T; Larsson K; Palange P; Popov T; van Cauwenberge P; ; ;
    Allergy; 2008 May; 63(5):492-505. PubMed ID: 18394123
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Not Available].
    Bieri A; Kamber M; Sterchi M; Mullis PE
    Ther Umsch; 2014 Apr; 71(4):245-52. PubMed ID: 24670606
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Salmeterol xinafoate. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease.
    Brogden RN; Faulds D
    Drugs; 1991 Nov; 42(5):895-912. PubMed ID: 1723379
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Doping dose of salbutamol and exercise: deleterious effect on cancellous and cortical bones in adult rats.
    Bonnet N; Benhamou CL; Beaupied H; Laroche N; Vico L; Dolleans E; Courteix D
    J Appl Physiol (1985); 2007 Apr; 102(4):1502-9. PubMed ID: 17185495
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-Dose Inhaled Salbutamol Does Not Improve 10-km Cycling Time Trial Performance.
    Koch S; Ahn JR; Koehle MS
    Med Sci Sports Exerc; 2015 Nov; 47(11):2373-9. PubMed ID: 25856682
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.